| 查看: 1757 | 回复: 1 | |||
[交流]
gliosis和glioma有什么区别？ 已有1人参与
|
|
查了些文献都没有谈清楚，有大神指点一下嘛 gliosis指胶质增生，glioma是胶质瘤，但是有时候又不太能分清楚。 |
回复此楼» 猜你喜欢
系统今天又提示维护了，估计离放榜不远了
已经有15人回复
-
2026年国自然面上资助率
已经有7人回复
-
微信指数没变化，科研之友没阅读
已经有17人回复
-
申请2027年材料/化学类博士
已经有5人回复
-
你们的时间戳变了吗
已经有4人回复
-
小木虫看见有人已经知道结果了
已经有17人回复
-
今年的WR进展到哪一步了？
已经有9人回复
-
产物和副产物价值比较
已经有5人回复
-
时间戳他又来了
已经有17人回复
-
这个自发加氧反应的机理是什么？
已经有7人回复
zirow
木虫 (小有名气)
- 应助: 2 (幼儿园)
- 金币: 3751.8
- 红花: 3
- 帖子: 82
- 在线: 234.8小时
- 虫号: 1924189
- 注册: 2012-08-04
- 性别: MM
- 专业: 金融学
|
Gliosis versus glioma?: don't grade until you know. Marie Rivera-Zengotita Anthony T Yachnis Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, USA. Advances in anatomic pathology (Impact Factor: 3.22). 07/2012; 19(4):239-49. DOI: 10.1097/PAP.0b013e31825c6a04 Source: PubMed ABSTRACT A major challenge in the routine practice of surgical neuropathology is the distinction between reactive astrocytosis, which may be because of non-neoplastic and neoplastic conditions, and a low-grade infiltrating diffuse astrocytoma [World Health Organization (WHO) grade II]. This can be particularly challenging with small biopsies that often yield limited amounts of tissue for pathologic study, especially considering the marked differences in prognosis and therapy after a pathologic diagnosis. This paper will review some basic principles of gliosis as an astrocytic reaction to a wide range of central nervous system insults and focus on some common diagnostic pitfalls such as (1) gliosis associated with brain tumor mimics, including demyelinating disease and infections, (2) gliosis associated with nonglial tumors such as craniopharyngioma, hemangioblastoma, metastases, and central nervous system lymphoma. New diagnostic methods have facilitated the differentiation between reactive astrocytosis and the diffuse gliomas. Of these, the use of mutated isocitrate dehydrogenase-1 (IDH-1) as a marker of diffuse infiltrating astroctomas, oligodendrogliomas, and a subset of glioblastomas (secondary glioblastomas) is particularly exciting for tissue diagnosis and patient prognosis. In addition IDH-1 may be useful to distinguish a diffuse infiltrating glioma from low-grade "focal" neoplasms such as the pilocytic astocytoma in histologically ambiguous cases. The discovery of BRAF mutations as molecular signatures of some pilocytic astrocytomas, gangliogliomas, and pleomorphic xanthoastrocytomas has provided another diagnostic tool for the pathologist. Only after a definitive diagnosis of a diffuse infiltrating glioma or a focal glioma is made should a tumor grade be applied and some practical issues in current glioma grading are provided. |
2楼2014-07-24 09:58:35